The company has designed, synthesized, patented, and tested in preclinical cancer models multiple retinoic acid nuclear receptor gamma agonists. These compounds promote development of tumor infiltrating T-lymphocytes and have anti-cancer activities through stimulation of the immune system, rather than through direct cytotoxic effects on tumor cells. They are effective in animal models of non-small cell lung cancer and multiple other types of cancers. The company is planning to conduct clinical trials in cancer patients with at least one of these compounds.
Immuno-oncology Autoimmune Therapeutics Neurotherapeutics